Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811.

CXCR4 is a chemokine and chemokine receptor pair playing critical roles in tumorigenesis. Overexpression of C-X-C chemokine receptor type 4 (CXCR4) is a hallmark of many hematological malignancies including acute myeloid leukemia, chronic lymphocytic leukemia and non-Hodgkin's lymphoma, and generally correlates with a poor prognosis. A highly potent competitive antagonist of CXCR4, WZ811, recently has been identified with suppression of cancer cells aggressive in a variety of cancers. However, the effects of WZ811 on chronic lymphocytic leukemia cells have not yet been defined. The effect of WZ811 on chronic lymphocytic leukemia cells TF-1 and UT-7 cells in proliferation, colony formation, and cell migration in vitro were measured respectively. Decreased in cell viability, colony formation, migration, and survival with cell cycle arrest and higher sensitivity to docetaxel in vitro was observed upon WZ811 treatment. In mouse xenograft models developed with human leukemia cells, WZ811 exhibited tumor growth inhibition. Collectively, we have demonstrated that CXCR4 inhibition by WZ811 has the potential for the treatment of human hematological malignancies. This study demonstrated that WZ811 may be a novel approach in the treatment of chronic lymphocytic leukemia.

[1]  Byoungduck Park,et al.  Onbaekwon Suppresses Colon Cancer Cell Invasion by Inhibiting Expression of the CXC Chemokine Receptor 4 , 2016, Integrative cancer therapies.

[2]  A. Langerak,et al.  Targeting Signaling Pathways in Chronic Lymphocytic Leukemia. , 2016, Current cancer drug targets.

[3]  K. Ahn,et al.  Embelin Inhibits Invasion and Migration of MDA‐MB‐231 Breast Cancer Cells by Suppression of CXC Chemokine Receptor 4, Matrix Metalloproteinases‐9/2, and Epithelial–Mesenchymal Transition , 2016, Phytotherapy research : PTR.

[4]  Hiroki Takahashi,et al.  Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists , 2016, BMC Cancer.

[5]  Zhiyong Zhang,et al.  Chemokines and their receptors in lung cancer progression and metastasis , 2016, Journal of Zhejiang University-SCIENCE B.

[6]  Zhidong Wang,et al.  Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell , 2016, Tumor Biology.

[7]  Y. Truong,et al.  G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis , 2016, PloS one.

[8]  A. Mueller,et al.  Cell migration towards CXCL12 in leukemic cells compared to breast cancer cells. , 2016, Cellular signalling.

[9]  R. Greil,et al.  Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors , 2016, Haematologica.

[10]  L. Rassenti,et al.  Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway , 2015, Oncotarget.

[11]  N. Chiorazzi,et al.  BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia , 2015, Leukemia.

[12]  D. Oupický,et al.  Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery , 2016, Current Pharmacology Reports.

[13]  Jiansong Wang,et al.  Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer. , 2015, Genetics and molecular research : GMR.

[14]  Ya-Jie Wang,et al.  Catalpol induces oligodendrocyte precursor cell-mediated remyelination in vitro. , 2015, American journal of translational research.

[15]  M. Lian,et al.  Dysregulation of zinc finger protein, X-linked (ZFX) impairs cell proliferation and induces apoptosis in human oral squamous cell carcinorma , 2015, Tumor Biology.

[16]  Zhaoming Li,et al.  Six1 promotes glioblastoma cell proliferation and invasion by upregulation of connective tissue growth factor. , 2015, American journal of cancer research.

[17]  D. Colomer,et al.  CXCR5-mediated shaping of the lymphoid follicle in chronic lymphocytic leukemia. , 2014, Cancer discovery.

[18]  D. Weisenburger,et al.  Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease , 2014, Molecular medicine.

[19]  Ruo-fan Huang,et al.  FRAS1 knockdown reduces A549 cells migration and invasion through downregulation of FAK signaling. , 2014, International journal of clinical and experimental medicine.

[20]  Zhidong Lv,et al.  Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. , 2014, International journal of clinical and experimental pathology.

[21]  T. Kipps,et al.  The pathogenesis of chronic lymphocytic leukemia. , 2014, Annual review of pathology.

[22]  Jian-yong Li,et al.  Role of chemokines and their receptors in chronic lymphocytic leukemia , 2014, Cancer biology & therapy.

[23]  J. Burger,et al.  Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemia—Focus on the B-Cell Receptor , 2013, Clinical Cancer Research.

[24]  P. Nannini,et al.  CCR4 expression in a case of cutaneous Richter’s transformation of chronic lymphocytic leukemia (CLL) to diffuse large B‐cell lymphoma (DLBCL) and in CLL patients with no skin manifestations , 2011, European journal of haematology.

[25]  P. Dorrestein,et al.  Elucidating the CXCL12/CXCR4 Signaling Network in Chronic Lymphocytic Leukemia through Phosphoproteomics Analysis , 2010, PloS one.

[26]  V. Golubovskaya,et al.  Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo , 2009, Cell cycle.

[27]  K. Shokat,et al.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. , 2009, Blood.

[28]  Hirokazu Tamamura,et al.  Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. , 2005, Blood.

[29]  J. Barretina,et al.  CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease , 2003, Annals of Hematology.